The medicine "Rosuvastatin" describes the instructions for use as a
lipid-lowering drug from the group of statins. The basis of the action of this selective agent is the
competitive inhibition of HMG-CoA reductase. As a result of using the drug "Rosuvastatin" (the instructions for use confirm this), LDL catabolism increases several times, the rate of hepatic LDL receptors increases, and the amount of VLDL decreases. As for the pharmacokinetic properties of this hypolipidemic drug, a pronounced therapeutic effect from its administration is observed seven days after the start of the course of therapy, reaching its maximum result after four weeks.
The manufacturer recommends taking Rosuvastatin tablets to people suffering from a mixed form of hypercholesterolemia (type IIb) or hypercholesterolemia IIa (including heterozygous) as a supplement to the diet.
Moreover, this hypolipidemic drug is most effective when other methods of treatment (physical activity, weight loss) do not lead to the achievement of a proper therapeutic result. In addition, the use of the Rosuvastatin selective agent is advised by the instructions for use as an adjuvant during the treatment of homozygous family type hypercholesterolemia .
It is strictly forbidden to prescribe these tablets if the patient has severe liver diseases, myopathy or severe renal impairment. During pregnancy, it is also not worth taking the lipid-lowering agent "Rosuvastatin". This medicine is contraindicated in the lactation period. In addition, it is not recommended to take these tablets simultaneously with cyclosporine or with increased sensitivity to their components. Persons who have not reached the age of eighteen years old should also not be prescribed the selective agent “Rosuvastatin”. Instructions for use do not recommend taking it in case of alcohol dependence, established renal failure or liver disease.
With great care, this hypolipidemic drug should be used by people suffering from electrolyte, endocrine or metabolic disorders, hypothyroidism or arterial hypotension. With sepsis, uncontrolled epilepsy, proteinuria, extensive injuries and surgical interventions, you should also refuse to take the medicine "Rosuvastatin". In addition, hereditary muscle diseases and age over sixty five are relative contraindications.
In conclusion, it should be said about possible adverse reactions, the appearance of which can be triggered by the use of Rosuvastatin. For example, many patients complain of abdominal pain, constipation, dizziness, and nausea. In addition, there is a small risk of developing myopathy, proteinuria, asthenic syndrome and myalgia.